Six weeks is a long time to sit in the unknown, but that’s how long I waited to find out if the 11mm tumour growing in my ...

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management will be ...

Oral, non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion ...

A consortium of leading European neurotechnology experts is developing a battery-less implant to treat cancer, severe ...

Jodie Donovan never liked wearing high heels. She struggled to walk in them, feeling unstable and off-balance. Even taking a ...

STOCKHOLM, SE / ACCESS Newswire / July 29, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing ...

Nerve damage generally happens slowly, says Isha Gupta, M.D., neurologist. So you might be able to catch it and prevent it ...

Study highlights novel epigenomic modulation in the central nervous system as a key mechanism for SRP-001's analgesic effects ...

The diabetes drugs Ozempic and Wegovy have been linked to an increased risk of sudden vision loss and blindness due to a rare ...

Treatment with HCCP led to significant improvements in pain, sleep quality, mood, and overall quality of life in patients with PNI.

Meet 12 biotech companies with promising genetic disease therapies that successfully closed funding rounds recently.